Business Description
Actinium Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00507W1071
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 45.97 | |||||
Equity-to-Asset | 0.47 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.04 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -6.36 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -2 | |||||
3-Year FCF Growth Rate | 0.3 | |||||
3-Year Book Growth Rate | -27.8 | |||||
Future 3-5Y EPS without NRI Growth Rate | 17.34 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 22.62 | |||||
9-Day RSI | 28.98 | |||||
14-Day RSI | 32.09 | |||||
6-1 Month Momentum % | -82.99 | |||||
12-1 Month Momentum % | -70 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 10.25 | |||||
Quick Ratio | 10.25 | |||||
Cash Ratio | 10.14 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.4 | |||||
Shareholder Yield % | -77.46 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -55504.94 | |||||
Net Margin % | -50512.35 | |||||
FCF Margin % | -43050 | |||||
ROE % | -99.37 | |||||
ROA % | -47.5 | |||||
ROIC % | -1275.72 | |||||
ROC (Joel Greenblatt) % | -1688.03 | |||||
ROCE % | -57.94 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 413.33 | |||||
PB Ratio | 1.01 | |||||
Price-to-Tangible-Book | 1.01 | |||||
EV-to-EBIT | 0.85 | |||||
EV-to-Forward-EBIT | -0.12 | |||||
EV-to-EBITDA | 0.87 | |||||
EV-to-Forward-EBITDA | -0.12 | |||||
EV-to-Revenue | -472.42 | |||||
EV-to-Forward-Revenue | 5246.5 | |||||
EV-to-FCF | 1.1 | |||||
Price-to-Net-Current-Asset-Value | 1.09 | |||||
Price-to-Net-Cash | 1.11 | |||||
Earnings Yield (Greenblatt) % | 117.65 | |||||
FCF Yield % | -90.02 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Actinium Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.074 | ||
EPS (TTM) (€) | -1.274 | ||
Beta | -0.23 | ||
Volatility % | 100.94 | ||
14-Day RSI | 32.09 | ||
14-Day ATR (€) | 0.058019 | ||
20-Day SMA (€) | 1.2231 | ||
12-1 Month Momentum % | -70 | ||
52-Week Range (€) | 1.07 - 9.11 | ||
Shares Outstanding (Mil) | 31.2 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Actinium Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Actinium Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Actinium Pharmaceuticals Inc Frequently Asked Questions
What is Actinium Pharmaceuticals Inc(STU:7AY1)'s stock price today?
When is next earnings date of Actinium Pharmaceuticals Inc(STU:7AY1)?
Does Actinium Pharmaceuticals Inc(STU:7AY1) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |